On-demand Webinar
Biosimilar Adoption: Past Experiences and Future Opportunities
Pharmacists and Biosimilars
Pharmacists are well positioned to help oversee the integration of biosimilars into patient care. Pharmacists have the opportunity to educate providers and patients about the biosimilar landscape and help implement an efficient workflow to support biosimilar adoption and use.
This resource center provides pharmacists with meaningful information and resources that will allow them to better understand biosimilars, their economic impact, as well as how to better implement biosimilars in therapeutic areas within various practice settings.
Resource News
Take note of recently added and upcoming resources.
Engaging the Experts: A New Landscape: Biosimilars in Multiple Sclerosis
Learn from experts in the field on Multiple Sclerosis.
Accelerating the Adoption of Biosimilars
A recent report that was part of an ASHP and ASHP Foundation project, Accelerating the Adoption of Biosimilars, explored biosimilars’ current and future adoption in the United States.
Biosimilars by the Numbers
Rheumatology Biosimilars Landscape
In 2023, several adalimumab biosimilars from different manufacturers are anticipated to enter the US market for patient use. Adalimumab biosimilars have several unique considerations, such as interchangeability and concentration, that will impact pharmacy practices and workflows. Understanding the various adalimumab biosimilar products available and considerations surrounding these products with regard to workflow and patient use is critical.
More information
Multiple Sclerosis Biosimilars Landscape
Natalizumab was approved in 2004 for the treatment of patients with relapsing forms of multiple sclerosis (MS) and in 2008 to treat moderate-to-severe-Crohn’s disease. In July 2022 the Food and drug Administration (FDA) accepted a Biologics License Application (BLA) for a proposed biosimilar to natalizumab.
More information
2023 Biosimilars Report
Recent report looks prescriber trends for rheumatology, gastroenterology, dermatology, adalimumab biosimilars, and ophthalmology. It also looks ahead to new and upcoming biosimilars launches, and the adalimumab biosimilars pipeline
More information
The U.S. Generic & Biosimilar Medicines Savings Report
Published in 2022 by the Association for Accessible Medications. The report leads with, "Savings From Generics and Biosimilars Continue To Grow, but Face Future Headwinds. More than $2.6 trillion in savings from medications used to treat nearly every health condition."
More information